Benefits of New Cholesterol Drug Outweighs Risks and Wins Green Light From US Experts

by Julia Samuel on  June 10, 2015 at 4:06 PM Drug News
RSS Email Print This Page Comment
Font : A-A+

A US advisory panel urged regulators to approve a new cholesterol-lowering drug that reduces mortality from cardiovascular disease.
Benefits of New Cholesterol Drug Outweighs Risks and Wins Green Light From US Experts
Benefits of New Cholesterol Drug Outweighs Risks and Wins Green Light From US Experts

The panel voted 13 to three in favor, saying that makers Regeneron and Sanofi had shown that the benefits of Praluent (alirocumab) lowering bad cholesterol (LDL-C) outweigh its risks.

Elias Zerhouni, Global research and development president, Sanofi said, "We are pleased with the committee's recommendation to approve Praluent. Our clinical trial program focused on patients with high unmet need in which Praluent delivered significant reductions in LDL-C on top of statins and other lipid-lowering therapies."

The drug, which is injected, works differently from statins. If approved, Praluent would be the first fully human monoclonal antibody targeting the PCSK9 enzyme.

Source: AFP

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
Notify me when reply is posted
I agree to the terms and conditions

Related Links

More News on:

Cholesterol High Cholesterol Drug Toxicity Heart Attack Diet Lifestyle and Heart Disease Body Mass Index Signature Drug Toxicity Cholesterol - The Enigma Chemical Liposuction Heart Attack- Lifestyle Risks 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive